Colistin resistance dynamics in Pseudomonas aeruginosa under biofilm and planktonic growth
Antimicrobial Agents and Chemotherapy · 2025-10 · 69 (10)
DOI: 10.1128/aac.00421-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025-10. Verfasst von Angie C Alarcon Rios und 8 weiteren Autor:innen. Beteiligte Einrichtung: Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Biofilms, Colistin, Anti-Bacterial Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission.
Abstract (Originalsprache)
Pseudomonas aeruginosa is a major pathogen in chronic biofilm-associated lung infections, particularly in patients with cystic fibrosis. Colistin is commonly used to treat these infections, although there is little understanding of how resistance evolves when cells are grown within biofilms. The current study compared the phenotypic dynamics and genetic adaptations of colistin resistance between planktonic and biofilm-grown P. aeruginosa . Using an in vitro experimental evolution approach, we passaged planktonic and biofilm cultures over 10 days under static or progressively increasing colistin concentrations. Population analysis profiling was performed daily to track resistance dynamics and heterogeneity. Whole-genome sequencing was conducted on evolved lineages. Biofilm-grown populations exhibited significantly slower resistance rates than planktonic cultures, particularly under treatments above 0.5 mg/L (1×MIC). Despite this initial delay, both biofilm- and planktonic cultures ultimately evolved similar frequencies of resistant subpopulations. Genetically, we observed shared mutations in canonical colistin resistance determinants such as phoQ and qseC . We also identified growth-mode-specific patterns: oprH mutations were primarily found in biofilm-evolved populations, while nfeD mutations were pervasive in planktonic cultures but rare in biofilms. Taken together, our results provide key insights into the role of biofilm in shaping the evolutionary trajectories of colistin resistance evolution in P. aeruginosa .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
- Institute of Biology, Leiden University, Leiden, the Netherlands.
- Department of Immunology and Microbiology, Costerton Biofilm Center, University of Copenhagen, Copenhagen, Denmark.
- Microbiology, Department of Biology, Utrecht University, Utrecht, the Netherlands.
- Centre for Human Drug Research, Leiden, the Netherlands.
ORCID-Profile: Angie C Alarcon Rios, Laura B Zwep, Bastienne Vriesendorp, Catherijne A J Knibbe, Oana Ciofu, Apostolos Liakopoulos, Linda B S Aulin, Daniel E Rozen, J G Coen van Hasselt
Förderung
- European Commission
Zitieren
APA
Alarcon Rios, A. C., Zwep, L. B., Vriesendorp, B., Knibbe, C. A. J., Ciofu, O., Liakopoulos, A., Aulin, L. B. S., Rozen, D. E., & van Hasselt, J. G. C. (2025). Colistin resistance dynamics in Pseudomonas aeruginosa under biofilm and planktonic growth. Antimicrobial Agents and Chemotherapy, 69(10). https://doi.org/10.1128/aac.00421-25
Vancouver
Alarcon Rios AC, Zwep LB, Vriesendorp B, Knibbe CAJ, Ciofu O, Liakopoulos A, et al. Colistin resistance dynamics in Pseudomonas aeruginosa under biofilm and planktonic growth. Antimicrobial Agents and Chemotherapy. 2025;69(10). doi:10.1128/aac.00421-25
BibTeX
@article{AlarconRios2025,
author = {Alarcon Rios, Angie C and Zwep, Laura B and Vriesendorp, Bastienne and Knibbe, Catherijne A J and Ciofu, Oana and Liakopoulos, Apostolos and Aulin, Linda B S and Rozen, Daniel E and van Hasselt, J G Coen},
title = {Colistin resistance dynamics in Pseudomonas aeruginosa under biofilm and planktonic growth},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {10},
doi = {10.1128/aac.00421-25}
}
EUVIMED